SCHEMBL3742285

SCHEMBL3742285

COCCc1cccc([C@@H]2CNC[C@H]2C(=O)N2CCC(c3ccccc3)CC2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.66
LIPE Q05469 3/20 0.45
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
TPSAB1 Q15661 2/20 0.40
CHRM4 P08173 2/20 0.39
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
ADAM10 O14672 2/20 0.39
MMP2 P08253 2/20 0.39
MMP8 P22894 1/20 0.39
MMP12 P39900 1/20 0.39
ADAM17 P78536 1/20 0.39
CCR5 P51681 1/20 0.39
REN P00797 1/20 0.38
KCNH2 Q12809 1/20 0.38
APP P05067 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3742284 1.00 BACE1 (0.66) BACE1LIPEALDH1A1POLBLMNA
SCHEMBL3734291 0.90 BACE1 (0.69) BACE1ALDH1A1POLBLMNARAB9A
SCHEMBL3734292 0.90 BACE1 (0.69) BACE1ALDH1A1POLBLMNARAB9A
SCHEMBL4229205 0.86 BACE1 (0.59) BACE1LIPERENKCNH2
SCHEMBL14556184 0.86 BACE1 (0.59) BACE1LIPERENKCNH2
SCHEMBL3731194 0.86 BACE1 (0.59) BACE1LIPERENKCNH2
SCHEMBL15998560 0.83 BACE1 (0.66) BACE1ALDH1A1POLBLMNARAB9A
SCHEMBL3729031 0.81 BACE1 (1.00) BACE1ALDH1A1POLBADAM10MMP2
SCHEMBL3744550 0.78 LIPE (0.54) LIPEALDH1A1POLBLMNARAB9A
SCHEMBL3744548 0.78 LIPE (0.54) LIPEALDH1A1POLBLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354545-B2 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-01-15 US claimed
EP-2231558-B1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-09-03 EP disclosed
US-8354545-B2 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-01-15 US disclosed
US-8354545-B2 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-01-15 US disclosed
US-20100280009-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-11-04 US disclosed
US-20100280009-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280009-A1 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, PSEN1 BACE1 1/4885LIPE 2809/4885ALDH1A1 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.